Short-term shortage announced for ketamine, with a slightly longer one for vardenafil – while Hypurin insulin and Zovirax tablets have been signalled for deletion from market
Bayer’s Levitra 20 vardenafil 20mg (as hydrochloride trihydrate) tablet blister packs are currently in shortage and expected to be back in normal supply from 31 May, says the TGA.
The brand’s Adalat nifedipine 10mg tablet blister pack is expected to be in shortage until 31 August and the 60mg modified release tablet blister pack will be in shortage until 30 June.
However the 20mg and 30mg should still be available.
Normal supply of AstraZeneca’s Omnaris ciclesonide 50 microgram per actuation nasal spray bottle is expected from 21 May.
Pfizer’s DBL Gentamicin 10mg/1mL (as sulfate) injection ampoule is set to be in low supply until late June, due to manufacturing reasons.
Apotex and Pfizer’s Zoledronic acid (4 mg/100 mL bag and 4mg/5mL concentrated injection vial) are in shortage until end of June to early October.
And there are two ketamine shortages over the next month: Hospira’s Ketalar ketamine 200mg/2mL (as hydrochloride) injection vial and Apotex’s Ketamine (as hydrochloride) 200 mg/ 2 mL solution for injection ampoule are both signalled for shortages in April.
However Hospira expects their shortage to end very soon, on 7 April.
Browse the Medicine Shortages Information Initiative for more information and sponsor contact details.
Meanwhile the following items have been signalled for deletion from the market:
- GSK Zovirax Aciclovir 200mg Dispersible tablet blister pack (deletion from market 16 March 2018 due to discontinuation)
- GSK Wartec cream podophyllotoxin 1.5mg/g tube (deletion from market 9 April 2018 due to discontinuation)
- Aspen Hypurin Isophane insulin 100IU/mL injection multidose vial suspension (deletion from market 28 May 2018 due to discontinuation)
- Aspen Hypurin Neutral insulin 100IU/1mL injection multidose vial solution (deletion from market 1 March 2019 due to discontinuation)